By Christa Myers and Kevin Debbs, CRB
Emerging and virtual biopharmaceutical company’s ask themselves whether to outsource production to a contract manufacturing organization (CMO) or purchase equipment for in-house manufacturing?
At the core of the issue is brand protection. While outsourcing can minimize capital and labor costs, the challenge lies in the process of evaluating and selecting the right pharmaceutical CMO as your manufacturing partner. How can you minimize potential consequences, including damage to your brand and loss of market share and revenue? How can you minimize the risks to product quality, while ensuring that equipment, processes and procedures used in manufacturing will maintain the intended strength, integrity, safety, purity and quality of the drug or product? And how can you do it all within budget?